FAQ: Which US public health concerns cystatin C testing help alleviate?
04. Mar 2020 |
5 min read
In this segment we will answer questions our Product Manager for cystatin C and Product Specialist in the US get about cystatin C at exhibitions, conferences and client meetings. Today’s question is “Which US public health concerns can cystatin C testing help alleviate?".
Which US public health concerns can cystatin C testing help alleviate?
Chronic kidney disease (CKD) is a growing public health issue with an estimated prevalence of 15% among U.S adults . The high cost of treating end stage renal disease (ESRD) suggests that slowing CKD progression and developing targeted approaches to disease management should be a priority for healthcare systems in the US. Cystatin C testing could ensure that these priorities are met by enabling an unbiased assessment of renal function, which is central to diagnosis and management of kidney disease. In fact, cystatin C has been used to define a preclinical period of reduced kidney function that precedes conventional creatinine-based diagnosis of CKD by 10+ years [2,3].
Incorporating cystatin C testing into CKD patient care could also alleviate racial disparities in kidney disease outcomes, by allowing for assessment of renal function independent of a patient’s muscle mass. One such disparity is that African Americans who are diagnosed with CKD are three times as likely as Caucasians to develop ESRD . Bias inherent in equations used to estimate kidney function solely via creatinine is a significant contributor to this public health issue.
The CKD-EPI equation regarded as the “best overall index for kidney function,” accounts for the higher muscle mass observed in African Americans with a 15.9% increase in eGFR over that of their Caucasians counterparts . For a patient with below-average muscle mass, such an increase could delay diagnosis of CKD and interventions against progression into ESRD. In later stages of the disease, a 15.9% increase could also mean that an African American patient becomes eligible for dialysis or a kidney transplant much later than a Caucasian patient with the same prognosis.
Do you want to know more about Gentian's cystatin C immunoassay or cystatin C in general? Send an email firstname.lastname@example.org fill out the form below and our Product Manager for cystatin C will get in touch.
HEALTHCARE, A. D. I. (2017). Chronic kidney disease in African Americans: Puzzle pieces are falling into place. Cleveland Clinic journal of medicine, 84(11), 855.
Levey AS et al. (2009). A new equation to estimate glomerular filtration rate. Annals of internal medicine, 150(9), 604-612.
Gentian Cystatin C
Gentian’s cystatin C immunoassaywas launched in 2006. It is a Particle-Enhanced Turbidimetric Immunoassay (PETIA) for in vitro testing of cystatin C in human plasma and serum samples. The test has documented high inter-instrument accuracy on a wide range of clinical chemistry analysers and can be performed in as little as 10 minutes.